Ascendiant Maintains Buy Rating for Cingulate Inc with $62.00 Target

Ascendiant analyst Edward Woo maintains a Buy rating for Cingulate Inc with a price target of $62.00. The company's shares opened at $4.02. The analyst has a success rate of 32.72% and an average return of -8.1%. The stock has a Strong Buy consensus rating with a $25.00 average price target, implying a 521.89% upside from current levels.

Ascendiant Capital has maintained its "Buy" rating on Cingulate Inc. (CING, Financial), while simultaneously increasing the price target from $61.00 to $62.00 USD. The revised target represents a 1.64% increase from the previous target, as per analyst Edward Woo's update [1]. This positive adjustment aligns with Ascendiant's previous assessments, which have seen price target increases earlier this year.

Cingulate Inc., a clinical-stage biopharmaceutical company, utilizes its proprietary precision timed-release drug delivery platform to develop next-generation pharmaceutical products. The company focuses on treating Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and is exploring additional therapeutic areas to leverage its technology [1].

The company's shares opened at $4.02 on July 2, 2025. Analysts have forecasted an average target price of $28.80 for Cingulate Inc., with a high estimate of $61.00 and a low estimate of $8.00. The consensus recommendation from brokerage firms indicates an "Outperform" status [1].

Recent management changes at Cingulate Inc. have led to a delay in the company's quarterly report filing for the period ending June 30, 2025. The company cited the need for additional time to review and prepare its financial statements following the appointment of new leadership, including an interim CEO and executive chairman [2]. Despite the delay, the company anticipates no significant change in its financial results compared to last year.

Cingulate Inc. continues to focus on its lead ADHD asset, CTx-1301, and has submitted its New Drug Application (NDA) with the FDA. The company aims to launch CTx-1301 in mid-2026, following FDA acceptance in the fourth quarter of 2025 [3].

Ascendiant Capital's positive outlook on Cingulate Inc. is supported by the company's strong pipeline, proprietary technology, and market opportunities. The stock's Strong Buy consensus rating and high price target estimates suggest significant upside potential [1].

References:
[1] https://www.gurufocus.com/news/3074959/cing-ascendiant-capital-raises-price-target-to-62-maintains-buy-rating-cing-stock-news
[2] https://www.ainvest.com/news/cingulate-delays-q2-financial-report-filing-due-management-2508/
[3] https://www.marketscreener.com/news/stonegate-capital-partners-updates-coverage-on-cingulate-inc-cing-2q25-ce7c50dad88df425